Contact us now to get immediate help: 1-877-893-8276
Diversion and abuse of the prescription pain reliever OxyContin is a major problem, particularly in the eastern United States. The Drug Enforcement Administration (DEA) reports that, in the United States, oxycodone products, including OxyContin, are frequently abused pharmaceuticals. The pharmacological effects of OxyContin make it a suitable substitute for heroin; therefore, it is attractive to the same abuser population. Law enforcement reports indicate heroin abusers are obtaining OxyContin because the pharmaceutical drug offers reliable strength and dosage levels. In addition, if the abusers' health insurance covers an illness that the drug treats, the insurance provider may cover the cost of the drug. Conversely, OxyContin abusers who have never used heroin may be attracted to the lower priced heroin when their health insurance no longer pays for OxyContin prescriptions or when they cannot afford the high street-level price of OxyContin. For example the West Virginia, Hancock-Brooke-Weirton Drug Task Force reports that a local couple, recently sentenced for conspiracy to sell heroin, turned to heroin after their doctor refused to continue prescribing OxyContin and they could not afford the street price of the pharmaceutical. OxyContin abusers sometimes commit theft, armed robbery, and fraud to sustain their habits.
The illegal diversion, distribution, and abuse of oxycodone products, particularly OxyContin, appear to be concentrated most heavily in the East, according to respondents to the National Drug Intelligence Center (NDIC) National Drug Threat Survey 2000 and DEA reporting. OxyContin Tablet, commonly referred to as OxyContin, has become the oxycodone product of choice in Maine, Ohio, and West Virginia, and in portions of eastern Kentucky, Maryland, western Pennsylvania, and rural southwestern Virginia.
Kentucky-The Kentucky State Police reports that OxyContin is the drug of choice in eastern Kentucky. The Kentucky State Police in Hazard report a significant shift from cocaine and methamphetamine abuse to OxyContin and Tylox abuse. Tylox is another trade name oxycodone product.
Maine-The U.S. Attorney, District of Maine, identifies OxyContin as the most significant drug threat in the state.
Maryland-The Maryland Drug Early Warning System, a real-time substance abuse monitoring program, identifies oxycodone as a leading emerging drug of abuse in 2000. The DEA reports nearly 85 percent of 1999 arrests for writing false prescriptions in Maryland involved oxycodone products, including OxyContin.
Ohio-The Cincinnati Police Department's Pharmaceutical Diversion Squad reports a growing OxyContin threat. From January to October 2000, illicit drug dealers in Cincinnati diverted over 9,000 doses of OxyContin (31 percent of all diverted oxycodone products). During the same time period, 49 of the squad's 341 diversion investigations targeted OxyContin, resulting in 22 arrests.
Pennsylvania-The Cambria County Drug Task Force reports that, as of September 2000, almost 30 percent of its undercover drug purchases involved OxyContin, and 31 suspects were accused of distributing tens of thousands of dollars' worth of OxyContin.
West Virginia-The Gilbert Police Department reports OxyContin is the "worst" drug the department has ever encountered, with OxyContin abuse even surpassing marijuana abuse.
The prescription drug OxyContin contains the narcotic oxycodone hydrochloride and is available in controlled-release tablets of 10, 20, 40, and 80 milligrams. OxyContin is prescribed in the United States to treat moderate to severe pain and is abused for its heroin-like effects. The diversion and abuse of OxyContin have increased sharply since the drug became available in 1996, raising concerns among law enforcement and public health agencies.
Oxycodone hydrochloride is an opiate agonist. Opiate agonists provide pain relief by acting on opioid receptors in the spinal cord, brain, and possibly in the tissues directly, and provide the most effective pain relief available. Oxycodone has a high abuse potential and is prescribed for moderate to severe pain associated with injuries, bursitis, dislocations, fractures, neuralgia, arthritis, lower back pain, and cancer. It is also used postoperatively and for pain relief after childbirth. Individuals who take the drug repeatedly can develop a tolerance or resistance to its effects. Thus, a cancer patient who has developed a tolerance for the drug can take a dose of oxycodone on a regular basis that would be fatal to a person never exposed to oxycodone.
On February 28, 2003, the U.S. Attorney's Office for the Southern District of Indiana announced that an Indiana doctor was sentenced to serve 51 months' imprisonment following his guilty pleas to unlawful trafficking in OxyContin and healthcare fraud. Between July and December 2001, the doctor prescribed OxyContin to a woman in amounts that were not medically necessary. For example, in one 14-day period in November 2001, the doctor prescribed 860 80-mg tablets of OxyContin. From January through December 2001, $130,000 was paid by the Indiana Medicaid program for OxyContin prescribed to this individual. After the prescriptions written by the doctor had been filled, the OxyContin was allegedly sold for cash to several individuals in Jennings County. The woman pled guilty to unlawful trafficking in OxyContin and healthcare fraud and was sentenced in December 2002 to 41 months' imprisonment.
Source: U. S. Attorney's Office, Southern District of Indiana.
National Drug Intelligence Center (NDIC) National Drug Threat Survey 2003 (NDTS) data also indicate that OxyContin is frequently diverted. Nationally, NDTS 2003 data indicate that 67.0 percent of state and local law enforcement agencies report that OxyContin is commonly diverted and abused in their areas--a higher percentage than any other pharmaceutical drug. A higher percentage of state and local law enforcement agencies in the Southeast region report that OxyContin is commonly diverted and abused in their areas (83.9%) than agencies in the Northeast/Mid-Atlantic (75.0%), Great Lakes (65.4%), West Central (61.8%), Pacific (56.9%), and Southwest (28.6%) regions.
The price of diverted OxyContin varies. DEA drug price data indicate that diverted OxyContin typically is sold for $1 per milligram. For example, a 40-milligram OxyContin tablet typically sells for $40; however, the price may vary depending on availability and other factors.
The total amount of diverted OxyContin available is unknown; however, legitimate distribution of the drug has increased sharply since 2000, thereby making more of the drug available for diversion. DEA reports increases in the total amount of licit OxyContin distributed to pharmacies, hospitals, practitioners, midlevel practitioners, and teaching institutions from 14,002,125.38 grams in 2001, to 15,118,153.37 in 2002, to 16,982,548.32 in 2003. Most of the OxyContin tablets were distributed to pharmacies, where distribution increased from 13,244,842.07 grams in 2001, to 14,338,099.69 in 2002, to 16,164,721.94 in 2003. As legitimate distribution of OxyContin has increased since 2000, the theft of OxyContin also has increased. According to DEA, the theft of OxyContin dosage units increased from 260,688 (791 incidents) in 2000 to 464,312 (1,251 incidents) in 2003.
In contrast to the increased distribution of OxyContin since 2000, the number of investigations and arrests for OxyContin reported by DEA has declined, and Organized Crime Drug Enforcement Task Force (OCDETF) investigations and indictments have fluctuated. The number of DEA OxyContin-related investigations declined from 172 in 2001, to 140 in 2002, to 71 in 2003. The number of OxyContin-related arrests by DEA also declined from 202 in 2001, to 179 in 2002, to 141 in 2003. In contrast, the number of OCDETF OxyContin-related investigations fluctuated from 10 in fiscal year (FY) 2001 to 22 in FY2002, but declined to 13 in FY2003. The number of OCDETF indictments for OxyContin-related offenses increased each year from 7 in FY2001, to 31 in FY2002, to 40 in FY2003.
The number of oxycodone samples submitted for testing has fluctuated; however, oxycodone was one of the most analyzed drug items in 2002. According to DEA System to Retrieve Information from Drug Evidence (STRIDE) data, the number of oxycodone dosage units submitted for testing decreased from 74,148.3 in 2001 to 24,040.4 in 2002, but increased to 59,695.9 in 2003. National Forensic Laboratory Information System data for 2002 show that oxycodone was among the 10 most analyzed drug items in state and local forensic laboratories; however, oxycodone represented only 0.98 percent of total analyzed drug items.
According to data from the National Survey on Drug Use and Health (NSDUH), adults, particularly young adults, are more likely to abuse OxyContin than are adolescents. NSDUH data for 2002--the latest year for which such data are available--indicate that of the estimated 1,924,000 individuals who have used OxyContin nonmedically at least once in their lifetime, approximately 1,700,000 were aged 18 or older compared with 224,000 who were aged 12 to 17. Moreover, NSDUH data for 2002 show that the rates of lifetime OxyContin use were higher for individuals aged 18 to 25 (2.6%) than for those aged 12 to 17 (0.9%) or those aged 26 or older (0.5%).
Rates of use for OxyContin may be trending upward. MTF data indicate that past year use of OxyContin rose from 2002 to 2003, though not significantly, for eighth (1.3% to 1.7%), tenth (3.0% to 3.6%), and twelfth (4.0% to 4.5%) graders. The consequences of oxycodone (including OxyContin) use also appear to be rising.
According to Drug Abuse Warning Network (DAWN) data, the estimated number of emergency department (ED) mentions for oxycodone rose from 10,825 in 2000, to 18,409 in 2001, to 22,397 in 2002. DAWN data further indicate that the estimated number of ED mentions for oxycodone increased significantly in several DAWN reporting cities, particularly Detroit, where oxycodone ED mentions increased 249.0 percent from 2001 (45) to 2002 (157). The number of oxycodone-related treatment admissions to publicly funded facilities also appears to be increasing. According to the Treatment Episode Data Set (TEDS), the number of oxycodone-related admissions to publicly funded treatment facilities rose sharply from 138 in 1999, to 441 in 2000, to 1,039 in 2001, the latest year for which such data are available. (Oxycodone-related admissions are not reported by all states.)
Individuals who abuse OxyContin risk developing tolerance for the drug, meaning they must take increasingly higher doses to achieve the same effects. Long-term abuse of the drug can lead to physical dependence and addiction. Individuals who become dependent upon or addicted to the drug may experience withdrawal symptoms if they cease using the drug. Withdrawal symptoms associated with OxyContin dependency or addiction include restlessness, muscle and bone pain, insomnia, diarrhea, vomiting, cold flashes, and involuntary leg movements. Individuals who take a large dose of OxyContin are at risk of severe respiratory depression that can lead to death. Inexperienced and new users are at particular risk because they may be unaware of what constitutes a large dose and have not developed a tolerance for the drug. OxyContin abusers who inject the drug expose themselves to additional risks, including contracting HIV (human immunodeficiency virus), hepatitis B and C, and other blood-borne viruses.
In the near future, other pharmaceutical manufacturers are expected to release generic forms of OxyContin. It is unclear what effect this will have on the level of OxyContin abuse; however, more individuals may visit physicians to obtain OxyContin or its less expensive generic equivalent.
Find Top Treatment Facilities Near You
Speak with a Certified Treatment Assesment Counselor who can go over all your treatment options and help you find the right treatment program that fits your needs.
Discuss Treatment Options!
Our Counselors are available 24 hours a day, 7 days a week to discuss your treatment needs and help you find the right treatment solution.
© Copyright 1998 - 2017 All Rights Reserved. Content is protected under copyright laws, do not use content without written permission.